Large-vessel vasculitis
D Pugh, M Karabayas, N Basu, MC Cid… - Nature Reviews …, 2021 - nature.com
Large-vessel vasculitis (LVV) manifests as inflammation of the aorta and its major branches
and is the most common primary vasculitis in adults. LVV comprises two distinct conditions …
and is the most common primary vasculitis in adults. LVV comprises two distinct conditions …
A general introduction to glucocorticoid biology
S Timmermans, J Souffriau, C Libert - Frontiers in immunology, 2019 - frontiersin.org
Glucocorticoids (GCs) are steroid hormones widely used for the treatment of inflammation,
autoimmune diseases, and cancer. To exert their broad physiological and therapeutic …
autoimmune diseases, and cancer. To exert their broad physiological and therapeutic …
Benralizumab versus mepolizumab for eosinophilic granulomatosis with polyangiitis
Background Eosinophilic granulomatosis with polyangiitis (EGPA) is a vasculitis
characterized by eosinophilic inflammation. Benralizumab, a monoclonal antibody against …
characterized by eosinophilic inflammation. Benralizumab, a monoclonal antibody against …
EULAR definition of difficult-to-treat rheumatoid arthritis
Background Despite treatment according to the current management recommendations, a
significant proportion of patients with rheumatoid arthritis (RA) remain symptomatic. These …
significant proportion of patients with rheumatoid arthritis (RA) remain symptomatic. These …
2018 Update of the EULAR recommendations for the management of large vessel vasculitis
B Hellmich, A Agueda, S Monti, F Buttgereit… - Annals of the …, 2020 - ard.bmj.com
Background Since the publication of the European League Against Rheumatism (EULAR)
recommendations for the management of large vessel vasculitis (LVV) in 2009, several …
recommendations for the management of large vessel vasculitis (LVV) in 2009, several …
[HTML][HTML] Trial of tocilizumab in giant-cell arteritis
JH Stone, K Tuckwell, S Dimonaco… - … England Journal of …, 2017 - Mass Medical Soc
Background Giant-cell arteritis commonly relapses when glucocorticoids are tapered, and
the prolonged use of glucocorticoids is associated with side effects. The effect of the …
the prolonged use of glucocorticoids is associated with side effects. The effect of the …
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
JS Smolen, R Landewé, J Bijlsma… - Annals of the …, 2017 - ard.bmj.com
Recent insights in rheumatoid arthritis (RA) necessitated updating the European League
Against Rheumatism (EULAR) RA management recommendations. A large international …
Against Rheumatism (EULAR) RA management recommendations. A large international …
Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial
M Boers, L Hartman, D Opris-Belinski, R Bos… - Annals of the rheumatic …, 2022 - Elsevier
Background Low-dose glucocorticoid (GC) therapy is widely used in rheumatoid arthritis
(RA) but the balance of benefit and harm is still unclear. Methods The GLORIA …
(RA) but the balance of benefit and harm is still unclear. Methods The GLORIA …
Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis
Background Eosinophilic granulomatosis with polyangiitis is an eosinophilic vasculitis.
Mepolizumab, an anti–interleukin-5 monoclonal antibody, reduces blood eosinophil counts …
Mepolizumab, an anti–interleukin-5 monoclonal antibody, reduces blood eosinophil counts …
British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis
SL Mackie, C Dejaco, S Appenzeller… - …, 2020 - academic.oup.com
Background GCA is a large vessel vasculitis affecting older people, with the highest
incidence among persons 70–79 years of age [1]. Due to forecasted demographic changes …
incidence among persons 70–79 years of age [1]. Due to forecasted demographic changes …